First Time Loading...

Editas Medicine Inc
NASDAQ:EDIT

Watchlist Manager
Editas Medicine Inc Logo
Editas Medicine Inc
NASDAQ:EDIT
Watchlist
Price: 5.89 USD -1.83% Market Closed
Updated: May 17, 2024

Editas Medicine Inc
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Editas Medicine Inc
Total Liabilities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Total Liabilities Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Editas Medicine Inc
NASDAQ:EDIT
Total Liabilities
$145.9m
CAGR 3-Years
1%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Liabilities
$124.4B
CAGR 3-Years
-3%
CAGR 5-Years
13%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Total Liabilities
$38.8B
CAGR 3-Years
-7%
CAGR 5-Years
-1%
CAGR 10-Years
10%
Amgen Inc
NASDAQ:AMGN
Total Liabilities
$88B
CAGR 3-Years
18%
CAGR 5-Years
11%
CAGR 10-Years
7%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Liabilities
$5.1B
CAGR 3-Years
19%
CAGR 5-Years
23%
CAGR 10-Years
18%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Liabilities
$7.4B
CAGR 3-Years
8%
CAGR 5-Years
17%
CAGR 10-Years
22%

See Also

What is Editas Medicine Inc's Total Liabilities?
Total Liabilities
145.9m USD

Based on the financial report for Mar 31, 2024, Editas Medicine Inc's Total Liabilities amounts to 145.9m USD.

What is Editas Medicine Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
-2%

Over the last year, the Total Liabilities growth was 0%. The average annual Total Liabilities growth rates for Editas Medicine Inc have been 1% over the past three years , -2% over the past five years .